The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

Inclusion Criteria: * Diagnosed with type 2 diabetes for ≥3 months. Meets the diabetes diagnostic criteria established by the World Health Organization (WHO) in 1999. * Age ≥18 years, regardless of gender. * Body mass index ≥23.0 kg/m\^2. * HbA1c ≥7.5% and ≤11.0% at screening. * Concurrently taking metformin, with a metformin dose ≥1500 mg/day or the maximum tolerated dose (not less than 1000 mg/day), and may be combined with oral sodium-glucose cotransporter-2 inhibitors, thiazolidinediones, or alpha-glucosidase inhibitors. Combination oral medications must be at a stable dose for ≥8 weeks and continued during the study period. * For 8 weeks prior to screening, has been on a stable, regular regimen of premixed human insulin (including premixed insulin analogs) administered subcutaneously twice daily, with a total daily insulin dose of 15-50 units, in addition to diet and exercise control. * Has signed the informed consent form. * Willing and able to self-monitor blood glucose (SMBG) and record the diary card on time. * Fully understands the study purpose and can communicate well with the investigator, and can understand and comply with all requirements of this study. Exclusion Criteria: * Subjects who have previously tested positive for diabetes autoantibodies (including anti-glutamic acid decarboxylase antibodies, anti-islet cell antibodies, anti-insulin antibodies, anti-zinc transporter 8 antibodies, and anti-protein tyrosine phosphatase antibodies). * Fasting C-peptide level ≤0.6 ng/mL. * Used a glucagon-like peptide-1 (GLP-1) receptor agonist within the 3 months prior to screening. * Concomitant use of sulfonylureas, glinides, and dipeptidyl peptidase-4 inhibitors within the 3 months prior to screening. * History of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or a family history of these conditions. * History of acute/chronic pancreatitis. * Experienced a serious gastrointestinal disease (such as active ulcer) or underwent gastrointestinal surgery (except appendectomy or cholecystectomy) or had clinically significant gastric emptying abnormalities (such as pyloric obstruction, gastroparesis) or long-term use of medications that directly affect gastrointestinal motility, or deemed unsuitable for the study by the investigator within the 3 months prior to screening. * Concurrent severe diseases, including but not limited to severe cardiovascular, cerebrovascular, hepatic, or renal diseases, or severe diabetes-related complications, and deemed unsuitable for the study by the investigator. * Pregnant or breastfeeding female subjects, or subjects (including male subjects' female partners) with plans for pregnancy or sperm/egg donation within 3 months after the last dose, or unwilling to use at least one effective contraceptive method or device. * Unwilling to wear an invasive monitoring device. * Clear reasons that prevent the use of continuous glucose monitoring (CGM), such as severe allergy or skin conditions, and deemed unsuitable for the study by the investigator. * Subjects with skin lesions, scarring, redness, infection, or edema at the sensor application site that may affect the accuracy of sensor placement or interstitial glucose measurement. * Received long-term (continuous or cumulative ≥7 days) treatment with systemic corticosteroids or growth hormone that may affect blood glucose within 1 month prior to screening. * History of malignancy within the past 3 years, excluding basal cell carcinoma, squamous cell carcinoma, and any in situ cancers. * Participated in another drug or medical device clinical trial (except for registry studies) within the 3 months prior to screening. * Presence of severe psychiatric disorders or language barriers, unwilling or unable to fully understand and cooperate. * Experienced diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), or lactic acidosis (LAD) within the 3 months prior to screening. * Fasting triglycerides \>5.65 mmol/L (can be retested within one week) at screening. * History of alcohol or drug abuse (more than 14 units of alcohol per week \[1 unit = 360 mL of 5% beer, or 45 mL of 40% spirits, or 150 mL of 12% wine\]). * Known or suspected allergy to GLP-1 class drugs or excipients. * Any other reason deemed by the investigator to make the subject unsuitable for participation in the study.